CEO Executive AssistantPharma CEO global patient access time management is an obligation that has moved from the periphery to the center of pharmaceutical leadership accountability over the past decade. Global patient access programs, encompassing expanded access in markets awaiting regulatory approval, tiered pricing for low and middle income countries, WHO essential medicines engagement, and compassionate use frameworks that vary by jurisdiction, require CEO-level investment that is substantively different from the investor relations and domestic commercial management that traditionally defined the executive’s time portfolio.
The pressure for this investment comes from multiple directions simultaneously: international health organizations that are increasingly assertive about pharmaceutical company access obligations, patient advocacy communities with global reach, investor ESG frameworks that explicitly assess access program quality, and the reputational and regulatory consequences of visibly restrictive access policies in markets where disease burden is high and affordability is low.
Access Program Governance: The CEO’s Strategic Architecture
Global patient access programs require a governance architecture that reflects the CEO’s strategic priorities, not simply a compliance response to external pressure. The distinction matters because access programs that are designed as reputational management exercises are typically recognized as such by the stakeholders they are meant to engage, and produce worse outcomes than programs built around genuine commitment to access as a business and ethical objective.
The CEO must personally define the access governance framework: which programs receive investment (which products, which geographies, which patient populations), what the economic model for access programs looks like (full tiered pricing versus differential pricing versus donation models versus generic licensing), and how access program performance is measured and reviewed.
Without CEO-level governance definition, access programs tend to be inconsistently resourced, evaluated against poorly defined metrics, and managed by teams that lack the authority to make the cross-functional decisions that access programs require (pricing decisions, legal decisions about generic licensing, regulatory strategy decisions about seeking approval in low-income country markets).
WHO Essential Medicines Engagement
The WHO Model List of Essential Medicines is updated every two years and represents the global reference framework for which medicines should be available in national health systems worldwide. Inclusion on the WHO EML creates no legal obligation in most jurisdictions, but it has significant practical consequences: it influences national formulary decisions in low and middle income countries, it affects procurement decisions by UNICEF, GAVI, and other multilateral purchasers, and it creates a public accountability benchmark against which the pharmaceutical company’s access policies are evaluated.
The CEO of a company with products that meet the criteria for WHO EML inclusion, or that are candidates for inclusion in the next EML revision cycle, should invest time in understanding the EML application process and in engaging with WHO’s Health Technologies and Pharmaceuticals unit on access program design.
The WHO’s essential medicines program provides the framework for the biennial list review. Companies whose products are evaluated for EML inclusion can submit evidence packages and can participate in the expert committee review process in ways that the CEO should understand and, for strategically significant products, govern directly.
Tiered Pricing Strategy for Low and Middle Income Countries
Tiered pricing, pricing pharmaceutical products at differential levels based on a country’s ability to pay (typically indexed to GNI per capita or income category classifications), is the primary market-based mechanism for expanding access in low and middle income countries.
The CEO must invest time in tiered pricing strategy governance because pricing decisions in LMIC markets have implications beyond the countries directly affected. Parallel trade risk (products purchased at LMIC prices entering high-income markets through grey channels, undermining the commercial pricing structure) is a material concern for most pharmaceutical companies with significant LMIC pricing differentials.
Parallel trade management requires a combination of pricing strategy (limiting differentials to levels that do not make grey market arbitrage economically attractive), product packaging differentiation (country-specific packaging that enables identification and seizure of parallel imports), and legal enforcement in high-income markets where parallel imports are detected.
The CEO’s governance of tiered pricing must therefore balance the access objective (meaningfully lower prices in LMIC markets) with the commercial protection objective (maintaining the commercial pricing structure in high-income markets). This is a genuine strategic tension without a formula solution, and it requires CEO-level judgment in each product and market context.
Parallel Trade Management
Parallel trade of pharmaceutical products occurs when legally purchased pharmaceutical products are imported and resold in markets where they were not originally intended to be sold. Within the EU, parallel trade is generally legal under the principle of free movement of goods. Between the EU and non-EU markets, and in most other regions, parallel trade operates in legal grey areas or is legally prohibited but practically difficult to prevent.
The CEO must invest time in parallel trade monitoring and management governance as a component of the global patient access program, not as a separate commercial enforcement exercise. The framing matters: parallel trade management that is understood as a mechanism to protect access program integrity (preventing the commercial pricing structure from being undermined by grey market arbitrage of access-priced products) is more sustainable internally and externally than parallel trade management framed as price protection.
Specific governance obligations for the CEO include: reviewing the parallel trade monitoring program’s scope and methodology, ensuring that the legal enforcement strategy is calibrated to the commercial risk exposure, and engaging with the public communications around parallel trade management in a way that explains the access program rationale for parallel trade controls.
Expanded Access and Compassionate Use Across Jurisdictions
Expanded access and compassionate use frameworks for providing investigational medicines to patients outside of clinical trials vary significantly across jurisdictions. The US FDA framework (individual patient IND, intermediate-size patient population program, and treatment IND) differs from the EMA framework, which differs from national compassionate use programs in France, Germany, the UK, Japan, and other markets.
For a company conducting multi-country clinical programs, managing expanded access simultaneously across multiple regulatory frameworks is a significant operational burden. The CEO must govern this multi-jurisdictional program with sufficient attention to ensure that: access decisions are consistent with the company’s access policy, safety data collection requirements are met in each jurisdiction, and the expanded access program is not creating a de facto international commercial operation that triggers regulatory obligations.
The CEO should review the multi-jurisdictional expanded access program at least quarterly, with particular attention to which patient populations are being served (are the patients in the expanded access program comparable to the clinical trial population?), what safety signals are emerging from the expanded access population, and whether the program capacity is sustainable given the manufacturing and quality resources required.
For companies navigating both US and international compassionate use simultaneously, time management for pharma CEOs managing compassionate use programs provides a framework for governing individual patient IND programs and access program capacity.
NGO and Civil Society Relationship Management
Access-focused NGOs, including Medecins Sans Frontieres (MSF), Access Campaign, Oxfam’s access to medicines program, and the Access to Medicine Foundation, engage directly with pharmaceutical companies on access policy and conduct public rankings and assessments of company access program performance.
The Access to Medicine Foundation publishes a biennial Access to Medicine Index that ranks pharmaceutical companies on the quality and reach of their access programs. The methodology, which assesses company performance across governance, R&D, pricing, manufacturing, and intellectual property dimensions, is closely watched by institutional investors, government procurement agencies, and policy makers.
The CEO must invest time in engaging substantively with these NGO and civil society stakeholders, not simply managing the relationship through corporate affairs staff. NGOs that find the CEO unavailable or disengaged from access policy discussions will publish accordingly, and the reputational impact of consistent poor performance in access assessments is increasingly material to institutional investor sentiment.
Engagement with NGOs on access policy should be treated as a genuine dialogue rather than a communications exercise. The organizations have substantive expertise in access barriers and have documented the consequences of inadequate access programs with granularity that the CEO should be familiar with.
Investor ESG Requirements and Access Program Reporting
Institutional investors and ESG rating agencies have increasingly incorporated pharmaceutical access program quality into their assessment frameworks. MSCI, Sustainalytics, and the Access to Medicine Foundation’s index are all referenced by major institutional investors in their pharmaceutical sector ESG evaluations.
The CEO must invest time in access program reporting that meets institutional investor expectations for specificity and transparency. Generic statements about the company’s commitment to global health are insufficient; investors are evaluating specific data on tiered pricing program scope, expanded access program utilization, LMIC market penetration, and affordability program results.
Conclusion: Pharma CEO Global Patient Access Time Management as Leadership Standard
Pharma CEO global patient access time management reflects the degree to which the CEO views global access as a genuine business and ethical obligation versus a reputational management activity. Companies whose CEOs invest substantively in access governance, WHO engagement, NGO relationships, and tiered pricing strategy build access programs that are more effective, more credible to external stakeholders, and more aligned with the long-term sustainability of the pharmaceutical business model.
As governments and international institutions continue to increase pressure on pharmaceutical companies to demonstrate access program quality, the CEO’s personal investment in this domain will increasingly distinguish the companies that navigate the policy environment effectively from those that do not.
Related Reading
For further context, explore How Pharma CEOs Balance Regulatory Affairs and Commercial Time and How Pharma CEOs Manage Time During Major Conference Season.